<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00277550</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919EUS42</org_study_id>
    <nct_id>NCT00277550</nct_id>
  </id_info>
  <brief_title>The Effects of Tegaserod vs. Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Evaluation of the Effects of Tegaserod (6 mg b.i.d) on Whole Gut Transit Time in Patients With Chronic Idiopathic Constipation and Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      To demonstrate the effects of tegaserod on gastrointestinal scintigraphic orocecal transit in&#xD;
      female patients with CC and upper GI symptoms of dyspepsia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of one week of tegaserod on the passage of content through the gut by radiological procedures.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PD effects of tegaserod on upper &amp; lower GI transit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate global well-being &amp; upper and lower GI symptoms in daily assessment of bowel habits and weekly global and individual symptom assessments</measure>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Constipation and Dyspepsia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod and Placebo</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females aged 18 to 64 years of age&#xD;
&#xD;
          -  Patients must present with two or more of the following criteria for chronic&#xD;
             constipation for at least 12 weeks prior to entering the study:&#xD;
&#xD;
               1. Less than 3 bowel movements per week&#xD;
&#xD;
               2. Hard or lumpy stools&#xD;
&#xD;
               3. Straining during bowel movements&#xD;
&#xD;
               4. Feeling of incomplete evacuation&#xD;
&#xD;
          -  Patients must report overlapping symptoms consistent with dyspepsia, such as mid-upper&#xD;
             abdominal discomfort characterized by early satiety, post-meal fullness and bloating&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a recent history of, or current frequency of diarrhea occuring more than&#xD;
             once per month off of laxatives&#xD;
&#xD;
          -  Clinically significant diagnosis of pelvic outlet obstruction or pelvic floor&#xD;
             dyssenergia as determined by the study physicians&#xD;
&#xD;
          -  Patients with constipation secondary to medication use as determined by the study&#xD;
             physician&#xD;
&#xD;
          -  Patients with clinically significant abnormal TSH levels at screening&#xD;
&#xD;
          -  Patients that have heartburn or abdominal pain as their predominant GI symptom&#xD;
&#xD;
          -  Evidence of cathartic colon or a history of laxative abuse&#xD;
&#xD;
               -  Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Talley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Crowell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>January 13, 2006</study_first_submitted>
  <study_first_submitted_qc>January 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2006</study_first_posted>
  <last_update_submitted>March 2, 2016</last_update_submitted>
  <last_update_submitted_qc>March 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Constipation, Tegaserod, Dyspepsia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

